%0 Journal Article
%T Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy
%A Kenji Ina
%A Ryuichi Furuta
%A Takae Kataoka
%A Satoshi Kayukawa
%J World Journal of Clinical Oncology
%D 2011
%I Baishideng Publishing Group Co. Limited
%R 10.5306/wjco.v2.i10.339
%X AIM: To examine whether administration of lentinan, purified ¦Â-1, 3-glucan, can prolong survival in advanced gastric cancer patients receiving S-1-based chemotherapy. METHODS: Since 2004, 78 patients with metastatic or recurrent gastric cancer have received S-1-based chemotherapy as first-line treatment. Survival, side effects, and the ratio of granulocytes/lymphocytes (G/L ratio) were compared between 2 groups of patients who received chemo-immunotherapy using lentinan and chemotherapy alone. RESULTS: Median overall survival was significantly longer in the former group than in the latter group [689 d (95% CI: 431-2339 d) vs 565 d (95% CI: 323-662 d), P = 0.0406]. In addition, the G/L ratio in patients who received lentinan was maintained around or below 2, which was significantly lower than that in patients who received chemotherapy alone (P < 0.001). CONCLUSION: Chemo-immunotherapy with lentinan offers a significant advantage over S-1-based chemotherapy alone in terms of survival in patients with advanced gastric cancer.
%K Gastric cancer
%K Lentinan
%K S-1-based chemotherapy
%U http://www.wjgnet.com/2218-4333/full/v2/i10/339.htm